Continuous intravenous to oral morphine switch in very premature ventilated infants: A retrospective study on efficacy, efficiency, and tolerability
Paediatric and Neonatal Pain · 2019
DOI: 10.1002/pne2.12011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Paediatric and Neonatal Pain, 2019. Verfasst von Phoï Duong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neonatal Intensive Care Unit CHI Créteil Créteil France. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Continuous intravenous (IV) morphine is commonly used in ventilated neonates. Oral route is theoretically feasible but data on oral morphine in ventilated premature infants are lacking.
Objective
To assess the efficacy, efficiency, and tolerability of a continuous intravenous to oral morphine switch protocol.
Design
Retrospective study.
Setting
Single level III center's neonatal intensive care unit. Patients Ventilated premature infants hospitalized in the NICU in 2016 and 2017, receiving continuous IV morphine with an expected ventilation course of at least 72 more hours. We excluded patients treated for withdrawal syndrome or palliative care.
Interventions
Continuous IV to oral morphine switch with the same initial cumulated daily dose. Main outcome measures Pain scores (ComfortNeo scale) and morphine doses were analyzed over time using Friedman's test in the 24 hours preceding and the 48 hours following the oral switch. Adverse effects attributable to opioids were collected.
Results
Seventeen infants were included with a median [IQR] gestational age at birth of 25.9 [24.6‐26.9] weeks and a median postnatal age at oral switch of 30 [22‐36] days. One patient's intravenous treatment had to be resumed because of a high ComfortNeo score. All others remained on oral morphine. No significant change over time was observed for ComfortNeo scores ( P = .15). Median [IQR] doses were 13.5 [10‐20] µg/kg/h in the IV period and significantly increased to 15 [10‐25] µg/kg/h in the oral period ( P = .009). No short‐term respiratory, digestive, or urinary adverse event was observed. After a median [IQR] duration of 13 [4‐20] days of oral morphine treatment, 11 (65%) patients showed signs of withdrawal. Upon hospital discharge, 16 infants (94%) had bronchopulmonary dysplasia and none had severe cerebral abnormality on brain imaging.
Conclusion
Oral morphine might be useful in ventilated neonates in the NICU but deserves further studies and additional safety assessment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neonatal Intensive Care Unit CHI Créteil Créteil France.
- CRESS INSERM 1153 INRA Université de Paris Paris France.
- Faculté de Médecine de Créteil Université Paris Est Créteil IMRB, GRC CARMAS Créteil France.
ORCID-Profile: Xavier Durrmeyer
Zitieren
APA
Duong, P., Tauzin, M., Decobert, F., Marchand, L., Caeymaex, L., & Durrmeyer, X. (2019). Continuous intravenous to oral morphine switch in very premature ventilated infants: A retrospective study on efficacy, efficiency, and tolerability. Paediatric and Neonatal Pain. https://doi.org/10.1002/pne2.12011
Vancouver
Duong P, Tauzin M, Decobert F, Marchand L, Caeymaex L, Durrmeyer X. Continuous intravenous to oral morphine switch in very premature ventilated infants: A retrospective study on efficacy, efficiency, and tolerability. Paediatric and Neonatal Pain. 2019. doi:10.1002/pne2.12011
BibTeX
@article{Duong2019,
author = {Duong, Phoï and Tauzin, Manon and Decobert, Fabrice and Marchand, Laetitia and Caeymaex, Laurence and Durrmeyer, Xavier},
title = {Continuous intravenous to oral morphine switch in very premature ventilated infants: A retrospective study on efficacy, efficiency, and tolerability},
journal = {Paediatric and Neonatal Pain},
year = {2019},
doi = {10.1002/pne2.12011}
}
EUVIMED